Advances in bioartificial liver devices

被引:258
作者
Allen, JW
Hassanein, T
Bhatia, SN
机构
[1] Univ Calif San Diego, Dept Bioengn, La Jolla, CA 92093 USA
[2] Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA
[3] Univ Calif San Diego, UCSD Liver Ctr, La Jolla, CA 92093 USA
关键词
D O I
10.1053/jhep.2001.26753
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
In light of the increasing incidence of liver disease and continuing shortage of donor organs, cell-based therapies are gaining attention as promising treatments for liver failure. Currently, several extracorporeal bioartificial liver devices are undergoing clinical evaluation. Their future use will depend on the choice and stabilization of the cellular component. Although cell lines offer a limitless cell source, primary hepatocytes may be preferred because of their broad expression of liver-specific functions. Xenogenic primary cells are available in large quantities, but immunologic and infectious concerns may necessitate the use of human cells or human-derived cells. To improve and maintain functional primary hepatocytes, bioreactor designs must provide architecture that supports cell attachment, cell-cell interaction, cell-matrix interaction, and potential for scale-up. While the safety of BAL devices has been established, there are no uniform standards of efficacy, which may vary with the etiology of the liver failure. Consensus is needed in clinical trial design, including choice of end points, use of controls, and indications for enrollment. Also, a better understanding of the interplay between liver regeneration and BAL therapy will be critical to optimizing the implementation of this modality.
引用
收藏
页码:447 / 455
页数:9
相关论文
共 138 条
[1]   Putative liver progenitor cells: Conditions for long-term survival in culture [J].
Agelli, M ;
DelloSbarba, P ;
Halay, ED ;
Faris, RA ;
Hixson, DE ;
Reid, LM .
HISTOCHEMICAL JOURNAL, 1997, 29 (03) :205-217
[2]  
AKAIKE T, 1993, GASTROENTEROL JPN, V28, P45
[3]   Liver assist systems: state of the art [J].
Arkadopoulos, N ;
Detry, O ;
Rozga, J ;
Demetriou, AA .
INTERNATIONAL JOURNAL OF ARTIFICIAL ORGANS, 1998, 21 (12) :781-787
[4]  
Ash S., 2000, International Journal of Artificial Organs, V23, P534
[5]  
ASH SR, 1992, INT J ARTIF ORGANS, V15, P151
[6]   A NOVEL BIOREACTOR DESIGN FOR IN-VITRO RECONSTRUCTION OF IN-VIVO LIVER CHARACTERISTICS [J].
BADER, A ;
KNOP, E ;
BOKER, K ;
FRUHAUF, N ;
SCHUTTLER, W ;
OLDHAFER, K ;
BURKHARD, R ;
PICHLMAYR, R ;
SEWING, KF .
ARTIFICIAL ORGANS, 1995, 19 (04) :368-374
[7]   Xenoantibody response of patients with severe acute liver failure exposed to porcine antigens following treatment with a bioartificial liver [J].
Baquerizo, A ;
Mhoyan, A ;
Shirwan, H ;
Swensson, J ;
Busuttil, RW ;
Demetriou, AA ;
Cramer, DV .
TRANSPLANTATION PROCEEDINGS, 1997, 29 (1-2) :964-965
[8]   Xenobiotic metabolism by cultured primary porcine hepatocytes [J].
Behnia, K ;
Bhatia, S ;
Jastromb, N ;
Balis, U ;
Sullivan, S ;
Yarmush, M ;
Toner, M .
TISSUE ENGINEERING, 2000, 6 (05) :467-479
[9]  
BERRY M, 1991, MONOLAYER CULTURE HE, P265
[10]   Effect of cell-cell interactions in preservation of cellular phenotype: cocultivation of hepatocytes and nonparenchymal cells [J].
Bhatia, SN ;
Balis, UJ ;
Yarmush, ML ;
Toner, M .
FASEB JOURNAL, 1999, 13 (14) :1883-1900